Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms, Hereditary Nonpolyposis 2Colorectal Neoplasms 2Recurrence 1Neoplasms 1Colonic Neoplasms 1Adenoma 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Mesalamine × Clear all
NCT04920149 2024-12-17

MesaCAPP

Karolinska University Hospital

Phase 2 Recruiting
150 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis

NCT03070574 2019-04-18

MesaCAPP

Medical University of Vienna

Phase 2 Terminated
8 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT02077777 2016-12-02

Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.

SOFAR S.p.A.

Phase 2 Completed
21 enrolled
Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT01894685 2015-12-08

Mesalazine Effects in Sporadic Colorectal Adenoma Patients

UMC Utrecht

Phase 2 Completed
74 enrolled

Adenoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡